Mobility for All?
J Am Acad Child Adolesc Psychiatry
© 2018 American Academy of Child and Adolescent Psychiatry Substantial numbers of children and adolescents are treated with second-generation antipsychotic medications (SGAs), and the cardiometabolic adverse effects of this medication class have raised concerns.1In the October 2017 issue of the Journal, Handen et al.2published a 16-week open-label extension study of youth 6 to 17 years of age with autism spectrum disorder treated with liquid metformin after a 16-week double-blinded, placebo-controlled clinical efficacy trial. The acute-phase and open-label extension trials demonstrated that liquid metformin was well tolerated, and significant improvements in body mass index z-scores were observed in the metformin-metformin and placebo-metformin groups.2Handen et al.2concluded that metformin can be effective for decreasing weight gain associated with SGA use and maintaining prior improvement in children and adolescents with autism spectrum disorder.
792 - 793
School of Medicine